Asarina Pharma: First patients begin Phase IIB trials of world’s first-ever therapy developed specifically to treat PMDD
Stockholm – April 24, 2018. The first patients arrived in clinics in Krakow, Poland and Berlin, Germany to take part in Phase IIB trials of the world’s first treatment for PMDD. CEO Peter Nordkild: “This is a milestone moment. Already having patients in the clinic, only ten days after the study opened, underlines the powerful need for a treatment that will alleviate the misery of the severest form of PMS.”The phase IIB study is recruiting 225-250 patients from Sweden, UK, Germany and Poland, to trial Sepranolone in PMDD. It’s an endogenous compound, naturally occurring in the brain, which